Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday.

APTO has been the topic of several other research reports. Canaccord Genuity set a $7.00 price objective on Aptose Biosciences and gave the company a “buy” rating in a research note on Wednesday, November 15th. Zacks Investment Research upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, February 13th. Finally, HC Wainwright set a $4.00 target price on Aptose Biosciences and gave the stock a “buy” rating in a research report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $5.00.

Aptose Biosciences (NASDAQ:APTO) opened at $2.82 on Thursday. Aptose Biosciences has a 12 month low of $0.78 and a 12 month high of $3.90. The company has a market capitalization of $82.73, a P/E ratio of -4.41 and a beta of 2.81.

An institutional investor recently raised its position in Aptose Biosciences stock. Acadian Asset Management LLC grew its stake in shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 44,421 shares of the biotechnology company’s stock after acquiring an additional 33,766 shares during the period. Acadian Asset Management LLC owned 0.17% of Aptose Biosciences worth $100,000 at the end of the most recent reporting period. Institutional investors own 1.07% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Aptose Biosciences (APTO) Downgraded by ValuEngine to Strong Sell” was published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.watchlistnews.com/aptose-biosciences-apto-downgraded-by-valuengine-to-strong-sell/1905102.html.

Aptose Biosciences Company Profile

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.